Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0E1WY
|
||||
Former ID |
DNC009026
|
||||
Drug Name |
EFIPLADIB
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Asthma [ICD10:J45] | Terminated | [529485] | ||
Structure |
Download2D MOL |
||||
Formula |
C40H35Cl3N2O4S
|
||||
Canonical SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)N3C4=C(C=C(C=C4)Cl)C(=C3CCNS<br />(=O)(=O)CC5=CC(=C(C=C5)Cl)Cl)CCCC6=CC=C(C=C6)C(=O)O
|
||||
InChI |
1S/C40H35Cl3N2O4S/c41-32-19-21-37-34(25-32)33(13-7-8-27-14-17-31(18-15-27)40(46)47)38(22-23-44-50(48,49)26-28-16-20-35(42)36(43)24-28)45(37)39(29-9-3-1-4-10-29)30-11-5-2-6-12-30/h1-6,9-12,14-21,24-25,39,44H,7-8,13,22-23,26H2,(H,46,47)
|
||||
InChIKey |
HIZOPJQOPKRKFM-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Cytosolic phospholipase A2 | Target Info | Inhibitor | [529940] | |
BioCyc Pathway | Phospholipases | ||||
KEGG Pathway | Glycerophospholipid metabolism | ||||
Ether lipid metabolism | |||||
Arachidonic acid metabolism | |||||
Linoleic acid metabolism | |||||
alpha-Linolenic acid metabolism | |||||
Metabolic pathways | |||||
MAPK signaling pathway | |||||
Ras signaling pathway | |||||
Vascular smooth muscle contraction | |||||
VEGF signaling pathway | |||||
Platelet activation | |||||
Fc epsilon RI signaling pathway | |||||
Fc gamma R-mediated phagocytosis | |||||
Glutamatergic synapse | |||||
Serotonergic synapse | |||||
Long-term depression | |||||
Inflammatory mediator regulation of TRP channels | |||||
GnRH signaling pathway | |||||
Ovarian steroidogenesis | |||||
Oxytocin signaling pathway | |||||
Choline metabolism in cancer | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
Endothelins | |||||
PDGFR-beta signaling pathway | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.